TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Actos Now for Prevention of Diabetes (ACT NOW)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women~* All ethnic groups~* 18 years of age and older~* Impaired glucose tolerance by glucose tolerance test (fasting glucose 95-125 mg/dl and 2 hr glucose of 140-199 mg/dl)~* At least one of the following:~  * One or more components of the insulin resistance syndrome (HDL \< 40 mg/dl in females and \<35 mg/dl in males, fasting triglycerides \> 150 mg/dl, blood pressure \> 135/85 mmHg, BMI \> 24 kg/m2, waist circumference \> 102 cm in men and \> 88 cm in women)~ * One or more first degree relatives with type 2 diabetes~ * History of gestational diabetes~ * Polycystic ovarian disease~ * Minority ethnic background (Mexican American, African American, Asian and Pacific Islanders, Native American)~Exclusion Criteria:~* Type 2 diabetes~* Previously treated with thiazolidinediones (ever) or metformin (within one year)~* Previously treated with a sulfonylurea, a meglitinide, an alpha glucosidase inhibitor for more than a week within last year or within the 3 months prior to randomization~* Previously treated with insulin (other than during pregnancy) for more than one week within the last year or within the 3 months prior to randomization~* Cardiovascular disease~* Hospitalization for treatment of heart disease or stroke in past 6 months~* New York Heart Association Functional Class \> 2~* Left bundle branch block or third degree AV block~* Aortic stenosis~* SBP \> 180 mmHg or DBP \> 105 mmHg~* Renal disease~* Anemia~* Hepatitis~* GI diseases (pancreatitis, inflammatory bowel disease)~* Recent or significant abdominal surgery~* Advanced pulmonary disease~* Chronic infections~* Weight loss \> 10% in past 6 months~* Pregnancy and childbearing~* Major psychiatric disorders~* Excessive alcohol intake~* Thiazide use \> 25 mg per day~* Non-selective beta blockers~* Niacin~* Systemic glucocorticoids~* Weight loss or weight gain medication~* Thyroid disease-suboptimally treated~* Active endocrine diseases (Cushing's, acromegaly)~* Plasma triglycerides over 400 mg/dl (despite treatment)~* History bladder cancer~* Hematuria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet similar to pioglitazone tablet
- Pioglitazone (Type: ACTIVE_COMPARATOR): Pioglitazone tablet similar to placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has T2DM.~* Participant is on dialysis on day of signing informed consent.~* Participant is unlikely to conceive or uses acceptable methods of birth control: hormonal contraceptive, intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, or vasectomy.~* Participant has hemoglobin A1c ≥7% and ≤9% measured at or within 2 weeks prior to Visit 4/Week -2.~* Participant is ≥85% compliant with study medication during the single-blind placebo run-in (as determined by tablet/capsule count) and compliant with diet, exercise and other run-in treatments during the run-in period.~Exclusion Criteria:~* Participant has a history of type 1 diabetes mellitus or a history of ketoacidosis.~* Participant is losing weight in a weight loss program and is not in the maintenance phase (defined as \<2 kg weight loss in 2 months), or intends to be involved in weight loss intervention outside that prescribed by the study.~* Participant has a clinically significant hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia).~* Participant has cirrhosis or active liver disease.~* Participant has been on dialysis for \< 6 months.~* Participant has been diagnosed with a significant cardiovascular disorder and has new or worsening signs or symptoms of congestive heart failure within 3 months of signing informed consent.~* Participant has severe active peripheral vascular disease.~* Participant has a history of malignancy ≤ 5 years prior to signing informed consent, or \> 5 years without documentation of remission/cure.~* Participant is under treatment for hyperthyroidism.~* Participant has a hypersensitivity or contraindication to glipizide.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 25 mg (Type: EXPERIMENTAL): None
- Glipizide 2.5 mg - 20 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with T2DM diagnosed for at least 12 months and treated with insulin glargine and Humalog®/Liprolog® or NovoLog®/NovoRapid® (at least 3 times daily, before each meal) in the 6 months prior to the screening visit.~* Signed written informed consent.~Exclusion criteria:~* At screening visit, age under legal age of adulthood.~* HbA1c \<6.5% or \>10.0% at screening.~* Diabetes other than T2DM.~* Pregnancy and lactation.~* Women of childbearing potential not protected by highly effective contraceptive method of birth control.~* Use of insulin pump in the 6 months before screening visit.~* Use of insulin other than insulin glargine and Humalog or NovoLog/NovoRapid in the 6 months prior to screening visit. Liprolog® is an European Union (EU) approved insulin lispro and is allowed in those countries where it is marketed.~* Use of Humalog/Liprolog or Novolog/NovoRapid less than 3 times daily, before each meal.~* Use of non-injectable peptides (eg, Glucagon-like peptide-1 (GLP-1) receptor-agonists or other peptides) in the 6 months prior to screening visit.~* Body mass index (BMI) \>=40kg/m² at screening visit.~* Hospitalization for diabetic ketoacidosis in the last 6 months before screening visit.~* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment, or injectable drugs) during the study period.~* The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SAR342434 (Type: EXPERIMENTAL): SAR342434 100 Unit/mL (U/mL) before meals intake on top of once daily (QD) Insulin Glargine, up to Week 26.
- Humalog (Type: ACTIVE_COMPARATOR): Humalog 100 U/mL before meals intake on top of QD Insulin Glargine, up to Week 26.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clobazam in Patients With Lennox-Gastaut Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have been \<11 years of age at the onset of LGS.~* Patient must have LGS.~* Patient must be on at least 1 AED.~* Parent or caregiver must be able to keep an accurate seizure diary.~Exclusion Criteria:~* Etiology of patient's seizures is a progressive neurologic disease. Patients with tuberous sclerosis will not be excluded from study participation, unless there is a progressive tumor.~* Patient has had an episode of status epilepticus within 12 weeks of baseline.~* Patient has had an anoxic episode requiring resuscitation within 6 months of screening.~* Patient has a clinically significant history of an allergic reaction or significant sensitivity to benzodiazepines.~* Patient is taking more than 3 concurrent AEDs.~* Patient has been on the ketogenic diet for less than 30 days prior to screening or suffers from frequent stooling.~* If the patient has a Vagal Nerve Stimulator (VNS), the settings have not been stable for at least 30 days prior to screening.~* Patient has taken corticotropins in the 6 months prior to screening.~* Patient is currently taking long-term systemic steroids (excluding inhaled mediation for asthma treatment) or any other daily medication known to exacerbate epilepsy. An exception will be made of prophylactic medication, for example, for idiopathic nephrotic syndrome or asthma.~* If the patient is taking felbamate, has been taking it for less than 1 year prior to screening.~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Clobazam Low Dose (Type: EXPERIMENTAL): None
- Clobazam Medium Dose (Type: EXPERIMENTAL): None
- Clobazam High Dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Ultra-high Dose Methylcobalamin for ALS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ALS patients within 12 months after clinical onset at the entry~* Updated Awaji combined with El Escorial criteria: definite, probably or laboratory supported probable~* Decline of ALSFRSR being 1 or 2 during observation period of 12 weeks~* Japanese Clinical Severity Scale 1 or 2~* Those who can visit the participating medical centers~Exclusion Criteria:~* Those who have tracheostomy~* Those who had NIPPV~* %FVC\<60%~* Those who have Chronic Obstructive Pulmonary Disease (COPD)~* Those who have symptoms and signs of B12 deficiency~* Those who had edaravone less than 4 weeks prior to entry~* Those who changed the schedule and dosing of riluzole~* Those who have dementia~* Those who have the possibility of pregnancy~* Those who have serious respiratory or cardiac diseases~* Those who have malignancies~* Those who participated other clinical trials within 12 weeks~* Those who have allergies to B12 and related compounds

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): intramuscular injection of saline solution
- methylcobalamin (Type: ACTIVE_COMPARATOR): intramuscular injection of methylcobalamin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is 21 years of age or older~* Subject is either not of childbearing potential OR subject must use an acceptable method of birth control if of childbearing potential~* Negative pregnancy test if female of childbearing potential~* Subject is in general good health~* Subject required treatment of joint pain within the last 90 days~* Subject has primary diagnosis of osteoarthritis (OA) of the hip or knee~Exclusion Criteria:~* Subject has a documented history of allergic reaction or intolerance to morphine or other opioids~* Subject is pregnant or breast-feeding~* Subject is receiving systemic chemotherapy~* Subject has a history of drug abuse/dependence/misuse or alcohol abuse/dependence~* Subject has history of major depressive disorder not controlled with medication~* Subject has any chronic pain syndrome (i.e., fibromyalgia) that may interfere with the symptoms of OA~* Subject has active gastrointestinal disease, with the exception of gastroesophageal reflux disease (GERD)~* Subject has a documented history of rheumatoid arthritis, uncontrolled inflammatory arthritis or non-steroidal anti-inflammatory drug (NSAID)-dependent inflammatory arthritis

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALO-01 (Type: EXPERIMENTAL): Up to 80 mg twice a day (bid)
- Placebo (Type: PLACEBO_COMPARATOR): Twice a day (bid)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Psilocybin for the Treatment of Cluster Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic cluster headache with at least one attack daily~* Episodic cluster headache with periods that are predictable and have a duration of approximately 2 months~* Attacks are managed by means involving no more than twice weekly triptan use (e.g., high-flow oxygen, heat/cold pack)~Exclusion Criteria:~* Axis I psychotic disorder (e.g. schizophrenia, bipolar I, depression with psychosis)~* Axis I psychotic disorder in first degree relative~* Unstable medical condition, severe renal, cardiac or hepatic disease, pacemaker, or serious central nervous system pathology~* Pregnant, breastfeeding, lack of adequate birth control~* History of intolerance to psilocybin, lysergic acid diethylamide (LSD), or related compounds~* Drug or alcohol abuse within the past 3 months (excluding tobacco)~* Urine toxicology positive to drugs of abuse~* Use of vasoconstrictive medications (i.e. sumatriptan, pseudoephedrine, midodrine) within five half-lives of test days~* Use of serotonergic antiemetics (i.e. ondansetron) in the past 2 weeks~* Use of antidepressant medications (i.e. amitriptyline, isocarboxazid, fluoxetine, citalopram) in the past 6 weeks~* Use of steroids or certain other immunomodulatory agents (i.e. azathioprine) in the past 2 weeks

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Psilocybin High Dose (Type: ACTIVE_COMPARATOR): None
- Psilocybin Low Dose (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Penehyclidine for PONV Prophylaxis After Strabismus Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I or II~* Aged 3-65 years~* Scheduled for elective strabismus surgery under general anesthesia~Exclusion Criteria:~* Had prior PONV~* Severe motion sickness~* A history of ophthalmic surgery~* Had received drugs known to have antiemetic effects in 24h before surgery

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Penehyclidine (Type: EXPERIMENTAL): Patients in this arm will receive penehyclidine after anesthesia intubation.
- Normal Saline (Type: PLACEBO_COMPARATOR): Patients in this arm will receive normal saline after anesthesia intubation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with hypercholesterolemia~Exclusion criteria:~* Age \< 18 or legal age of adulthood, whichever was greater~* LDL-C \< 100 mg/dL (\< 2.59 mmol/L) or \> 190 mg/dL (\> 4.9 mmol/L)~* Fasting serum triglycerides (TG) \> 400 mg/dL (\> 4.52 mmol/L)~* Known history of homozygous or heterozygous familial hypercholesterolemia~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ezetimibe 10 mg (Type: ACTIVE_COMPARATOR): Oral ezetimibe 10 mg capsule daily and subcutaneous (SC) placebo injection for alirocumab every 2 weeks (Q2W) for 24 weeks.
- Alirocumab 75/Up to 150 mg Q2W (Type: EXPERIMENTAL): SC injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe daily for 24 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metformin and Oral Contraceptives in PCOS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Irregular menses or anovulaty cycles~* High free testosterone \> 0.035 nmol/l or hirsutism~* PCO in vaginal US Criteria 1 and 2 OR 2 and 3~Exclusion Criteria:~* Age \> 18 years~* Postmenopausal~* Diagnosis diabetes mellitus~* Use of medicine known to affect hormones measured in the project~* Pregnancy or planned pregnancy during study period~* Non-Caucasian~* Previous tromboembolic disease~* Heavy smoker \> 35 years and BMI \> 35 kg/m2

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): metformin
- 2 (Type: ACTIVE_COMPARATOR): desorelle
- 3 (Type: ACTIVE_COMPARATOR): desorelle + metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Levosimendan and Myocardial Protection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥18 years~* intention to perform first-time multi-vessel CABG~Exclusion Criteria:~* unstable angina~* valvular disease~* diabetes mellitus treated with sulphonylurea drugs~* renal failure~* severe hepatic disease~* severe chronic obstructive pulmonary disease~* a history of prior CABG surgery~* recent myocardial infarction (MI) within the previous month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- L (Type: EXPERIMENTAL): None
- P (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Patients who completed the core CACZ885D2307 study (a patient is defined as having completed the core study if they completed the study up to and including the EOS visit with no major protocol deviations in the core).~2. Male and female patients that are ≥ 1 year of age at the time of the roll-over visit.~3. Parent or legal guardian written informed consent must be obtained before any assessment in the extension CACZ885D2307E1 study is performed.~Exclusion criteria:~1. Patients for who continued treatment in the CACZ885D2307E1 extension study is not considered appropriate by the treating physician.~2. Patients who discontinued from the core CACZ885D2307 study~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- canakinumab (Type: EXPERIMENTAL): Patients will receive a standard dose at an equivalent of 2 mg/kg s.c. of canakinumab (ACZ885) every 8 weeks. Possible dose and/or dosing regimen adjustments that can be administered include: 4 mg/kg s.c. (every 4 to 8 weeks) 6 mg/kg s.c. (every 4 to 8 weeks) 8 mg/kg s.c. (every 4 to 8 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete